Medical charities “slipping through cracks” of UK pandemic supportCharities have already been hit hard by the coronavirus pandemic and lockdown, and Cancer Research UK says it Share XMedical charities “slipping through cracks” of UK pandemic supporthttps://pharmaphorum.com/news/medical-charities-slipping-through-cracks-of-uk-pandemic-support/
Cancer Research UK cuts research funding as COVID-19 hits incomeCancer Research UK has cut funding to its research activities, as the charity faces a cut to its Share XCancer Research UK cuts research funding as COVID-19 hits incomehttps://pharmaphorum.com/news/cancer-research-uk-cuts-funding-as-covid-19-hits-income/
As cancer treatments evolve, so must investment mechanismsLast month’s American Society of Clinical Oncology (ASCO) meeting kicked off with a presentation from Professor Ruth Plummer, Share XAs cancer treatments evolve, so must investment mechanismshttps://pharmaphorum.com/views-analysis-oncology/as-cancer-treatments-evolve-so-must-investment-mechanisms/
CRUK tests drug combo for advanced pancreatic cancerCancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in Share XCRUK tests drug combo for advanced pancreatic cancerhttps://pharmaphorum.com/news/cruk-tests-drug-combo-for-advanced-pancreatic-cancer/
Genetic test can predict efficacy of chemotherapy in breast cancerResearchers have found that a genetic test can successfully predict whether chemotherapy would be beneficial for patients with Share XGenetic test can predict efficacy of chemotherapy in breast cancerhttps://pharmaphorum.com/news/genetic-test-can-predict-efficacy-of-chemotherapy-in-breast-cancer/
CRUK and Owlstone launch trial for cancer breath testCancer Research UK and Owlstone Medical have launched a clinical trial to develop a breath test that could Share XCRUK and Owlstone launch trial for cancer breath testhttps://pharmaphorum.com/news/cruk-and-owlstone-launch-trial-for-cancer-breath-test/
AstraZeneca looks to CRISPR to boost success ratesBetween 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below Share XAstraZeneca looks to CRISPR to boost success rateshttps://pharmaphorum.com/views-and-analysis/astrazeneca-crispr-boost-success-rates/
AZ and CRUK team up to go all-in on CRISPRAstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling Share XAZ and CRUK team up to go all-in on CRISPRhttps://pharmaphorum.com/news/az-cruk-crispr/
Cancer Research UK gives $4m funding to Glasgow Uni CML projectCancer Research UK granted £3.1m (nearly $4m) to a group of researchers at the University of Glasgow to Share XCancer Research UK gives $4m funding to Glasgow Uni CML projecthttps://pharmaphorum.com/news/experimental-leukaemia-study-grant/
